Autopoiesis Sciences, a San Francisco startup building artificial intelligence tools for scientific research, secured $11 million in seed funding led by Threshold Ventures. The round drew backing from Informed Ventures, Alpaca VC, VitalStage Ventures, Correlation Ventures, and Darkmode Ventures, the company announced September 30, though it declined to share its valuation.
The capital will fund development of Aristotle, an AI system designed to assist researchers with literature reviews, hypothesis generation, and experimental design. According to Threshold partner Lisa Xu, writing on Medium the following day, the firm sees potential for "building AI capable of autonomously performing scientific discovery." That's an ambitious target in a field where lab work still depends heavily on human intuition and years of domain expertise.
Threshold claims Aristotle now reaches thousands of researchers at organizations including Pfizer, the FDA, Harvard, GlaxoSmithKline, Merck, MIT, and several other pharmaceutical giants and academic institutions. According to the same Threshold post, the company itself has published no customer case studies or client logos on its website as of early October.
A Technical Bet on Metacognition
Autopoiesis employs what Threshold calls Metacognitive Steering, a method that adjusts how an AI model reasons through complex, multi-step investigations. The same underlying architecture powers Columbus-1, an autonomous research system the startup rolled out over the summer.
In a test reported in August 2026, security firm Xchg Labs said that Columbus-1 uncovered 21 distinct defects in BlueZ 5.86, the Linux Bluetooth stack, during a partnership audit. Eight qualified as zero-day vulnerabilities. Separately, the company said in a July 2026 blog post that the system designed a self-landing rocket, though details on that project remain sparse.
Results like these have drawn attention in circles where researchers face pressure to accelerate discovery timelines. Whether the technology can handle the messier realities of bench science remains an open question.
Leadership with Government Ties
CEO Joseph Reth leads the effort alongside co-founders Dr. Eike Gerhardt and Dr. Lawrence Callahan. Callahan brings decades of experience at the FDA and NIH; conference materials list him as affiliated with the Food & Drug Administration. Gerhardt, who holds a PhD, arrived in the United States on an O-1 visa for individuals with extraordinary ability. Reth started studying computer science at 14 and briefly attended San Francisco State, according to company materials.
The team size sits between 11 and 50 employees, per LinkedIn.
Earlier Moves and Market Context
This marks Autopoiesis's second known funding event. The company previously raised an undisclosed amount in a round led by Informed Ventures, the U.S. arm of GSR Ventures following a rebranding earlier in the year. Last August, it selected Oracle Cloud Infrastructure to support Aristotle's compute needs.
The raise arrives as venture investors warm to AI-driven research automation. Autoscience, which is constructing an automated AI research lab, pulled in $14 million from General Catalyst in March. Carta data suggests the median seed post-money valuation hovered around $21.6 million in the first quarter of this year, though those figures typically carry a reporting lag.
Autopoiesis has not outlined hiring plans or offered a timeline for its next product milestones. For now, the company appears focused on proving its technology can move from demonstrations to sustained use in working labs. That transition, if it happens, will determine whether Aristotle becomes infrastructure or remains a curiosity.
